Fig. 5
Determination of the anaplastic lymphoma kinase (ALK)–rearranged circulating tumor cells (CTC) optimal cutoff value in ALK-positive and ALK negative patients. a Prevalence of ALK-rearranged CTC in ALK-positive and ALK-negative patients. b Determination of the cutoff value for 3 ALK-rearranged CTC per ml blood by using receiver operating characteristic curve analysis. NPV negative predictive value, PPV positive predictive value